Engineering immune cells for next-generation therapies
Journal of Controlled Release · 2026-07 · 395 · 115012
DOI: 10.1016/j.jconrel.2026.115012 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Controlled Release, 2026-07. Verfasst von Maosen Han und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine; Shandong Key Laboratory of Targeted Drug Delivery and Ad…. Hauptthemen laut MEDLINE: Cell Engineering. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 227 Literaturangaben. Gefördert von: Natural Science Foundation of Shandong Province, Shandong University, National Natural Science Foundation of China.
Abstract (Originalsprache)
Immune cell engineering has emerged as a transformative frontier in medicine, reshaping therapeutic strategies for cancer, autoimmunity and infectious diseases. Advances in delivery technologies such as viral vectors, lipid nanoparticles and polymer-based systems, together with precise gene editing tools including mRNA platforms and CRISPR, have enabled the efficient programming of immune cells with enhanced specificity and potency. Chimeric antigen receptor (CAR) designs exemplify how synthetic receptors can redirect immune recognition and function, and are now being applied not only to T cells but also to macrophages, natural killer cells and dendritic cells. These innovations are expanding therapeutic opportunities from hematologic malignancies to solid tumors and chronic inflammatory disorders. In parallel, the transition from ex vivo manipulation to in vivo reprogramming is beginning to address manufacturing bottlenecks and improve clinical accessibility. Moreover, artificial intelligence is increasingly driving rational design of vectors, CAR structures, and signaling networks for next-generation therapies. In this Review, we summarize current approaches to immune cell engineering, compare the characteristics of delivery systems and the design of engineered regulatory elements, and highlight therapeutic applications, while also discussing the outstanding challenges of safety, persistence and microenvironmental barriers that must be overcome to achieve durable and widely applicable therapies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutics, School of Pharmaceutical Sciences, Cheeloo College of Medicine; Shandong Key Laboratory of Targeted Drug Delivery and Advanced Pharmaceutics, NMPA Key Laboratory for Technology Research and…
Förderung
- Natural Science Foundation of Shandong Province
- Shandong University
- National Natural Science Foundation of China
Zitieren
APA
Han, M., Lou, J., Pan, M., Xu, S., Jiang, X., & Jing, W. (2026). Engineering immune cells for next-generation therapies. Journal of Controlled Release, 395, 115012. https://doi.org/10.1016/j.jconrel.2026.115012
Vancouver
Han M, Lou J, Pan M, Xu S, Jiang X, Jing W. Engineering immune cells for next-generation therapies. Journal of Controlled Release. 2026;395:115012. doi:10.1016/j.jconrel.2026.115012
BibTeX
@article{Han2026,
author = {Han, Maosen and Lou, Jingzhao and Pan, Min and Xu, Shengkai and Jiang, Xinyi and Jing, Weiqiang},
title = {Engineering immune cells for next-generation therapies},
journal = {Journal of Controlled Release},
year = {2026},
volume = {395},
pages = {115012},
doi = {10.1016/j.jconrel.2026.115012}
}
EUVIMED